Tahir Yerlikaya

Dr. Tahir Yerlikaya

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Cancer Medicine
Verified
Journal Article
Open access
FGFatih Gürler
Fatih Gürler
FTFatih Tay
Fatih Tay
ZIZehra Sucuoglu Isleyen
Zehra Sucuoglu Isleyen
TYTahir Yerlikaya
Tahir Yerlikaya
EHEngin Hendem
Engin Hendem
NÖNuriye Özdemir
Nuriye Özdemir
Background: Neoadjuvant treatment is the standard treatment in locally advanced ESCC. However, the optimal chemotherapy regimen is not known.Method: This is a retrospective observational cohort study conducted with propensity score matching. Patients with resectable ESCC from 13 tertiary centers from Türkiye were screened between January 2011 and December 2021. We compared the efficacy and safety of neoadjuvant chemoradiotherapy with the CF and the CROSS regimens in patients with ESCC.Results: Three hundred and sixty‐two patients were screened. Patients who received induction chemotherapy (n = 72) and CROSS‐ineligible (n = 31) were excluded. Two hundred and fifty nine patients received neoadjuvant chemoradiotherapy. After propensity score matching (n = 97 in both groups), the mPFS was 18.4 months (95% CI, 9.3–27.4) and 25.7 months (95% CI, 15.6–35.7; p = 0.974), and the mOS was 35.2 months (95% CI, 18.9–51.5) and 39.6 months (95% CI 20.1–59.2; p = 0.534), in the CF and the CROSS groups, respectively. There was no difference between subgroups regarding PFS and OS. Compared with the CF group, the CROSS group had a higher incidence of neutropenia (34.0% vs. 62.9%, p < 0.001) and anemia (54.6% vs. 75.3%, p = 0.003) in all grades. On the other hand, there was no significant difference in grade 3–4 anemia, grade 3–4 neutropenia, and febrile neutropenia between groups. There were more dose reductions and dose delays in the CROSS group than in the CF group (11.3% vs. 3.1%, p = 0.026 and 34.0% vs. 17.5%, p = 0.009, respectively). The resection rate was 52.6% in the CF‐RT and 35.1% in the CROSS groups (p = 0.014).Conclusion: Favorable PFS and pCR rates and a comparable OS were obtained with the CROSS regimen over the CF regimen as neoadjuvant chemoradiotherapy in patients with ESCC.

27 October 2022
Verified
Book
Closed access
PDF file
EHEzgi Hacıhasanoğlu
Ezgi Hacıhasanoğlu
HKHatice Küçük
Hatice Küçük
EAEmine Ülkü Akçay
Emine Ülkü Akçay
AAAyfer Altaş
Ayfer Altaş
FAFatma Betül Asan
Fatma Betül Asan
EBErtuğrul Bayram
Ertuğrul Bayram
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejileri sayesinde her hastaya özgü bir şekilde planlanmaktadır. Tedavilerin bireyselleştirilmesi hususunda kuşkusuz yaş faktörünün önemi büyüktür ve tedavi kararlarında geriatrik popülasyon için seçilecek tedavi modalitesinin belirlenmesi oldukça hassas bir konudur. Zira tedavi seçeneklerinin herbirinin geriatrik popülasyonda kullanım şemaları, yan etki dağılımları ve yönetimleri farklılıklar göstermekte olup günlük pratiğimizde azımsanmayacak sıklıkta karşılaştığımız problemlerdendir.

1 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
NONeslihan Ozyurt
Neslihan Ozyurt
AAAli Alkan
Ali Alkan
BGBurcu Gülbağcı
Burcu Gülbağcı
MSMustafa Seyyar
Mustafa Seyyar
EAESRA AŞIK
ESRA AŞIK
MDMutlu Doğan
Mutlu Doğan
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis. Effective prognostic tools are essential to guide risk-adapted strategies following neoadjuvant chemotherapy (NACT). In this multicenter retrospective study, we evaluated 690 patients with locally advanced TNBC treated between 2010 and 2023 across 25 oncology centers. Patients were stratified into CPS-EG risk groups: low (0–1), intermediate (2–3), and high (≥4). The CPS-EG score was strongly associated with pathological complete response (pCR), recurrence, disease-free survival (DFS), and overall survival (OS). Five-year DFS rates were 80.6%, 53.2%, and 31.5% in the low-, intermediate-, and high-risk groups, respectively, while OS rates were 76.7%, 53.2%, and 48.8% (p<0.001). Multivariate analysis confirmed CPS-EG as an independent predictor of both DFS and OS after adjusting for clinicopathological factors. These findings highlight the CPS-EG score as a simple, cost-effective, and widely applicable prognostic tool that may improve post-NACT risk stratification and support treatment decisions, especially in resource-limited oncology settings.

15 April 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
SBSelami Bayram
Selami Bayram
BKBahadır Köylü
Bahadır Köylü
MMMartin Mildanoğlu
Martin Mildanoğlu
MAMustafa Serkan Serkan Alemdar
Mustafa Serkan Serkan Alemdar
TYTahir Yerlikaya
Tahir Yerlikaya
MOMustafa Ozdogan
Mustafa Ozdogan
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. Next-generation sequencing (NGS) enables molecular characterization and may identify clinically actionable alterations; however, real-world multicenter data linking genomic subgroups to survival outcomes remain limited. We aimed to characterize the molecular landscape of NGS-tested PDAC in a Turkish multicenter cohort and evaluate the association of key molecular alterations, including KRAS status and KRAS variant subgroups, with survival outcomes. Methods: We conducted a multicenter retrospective cohort study including patients with pathologically diagnosed PDAC between 2017 and 2025 who underwent tumor-based NGS in routine clinical practice. Overall survival (OS) was calculated from the date of metastasis, defined as the date of diagnosis for de novo metastatic disease and the date of first documented distant recurrence for recurrent cases. Progression-free survival (PFS) was calculated from the initiation of first-line systemic therapy for metastatic disease to progression or death. Survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Multivariable Cox proportional hazards models were constructed for OS and PFS using clinically relevant covariates selected a priori. Results: A total of 98 patients underwent molecular profiling, and survival analyses were performed in 92 patients with available OS/PFS data. KRAS mutations were detected in 83.7% (82/98) of patients, with predominant variants G12D (47.6%), G12V (30.5%), and G12R (12.2%). TP53 mutations were present in 59.2% (58/98) of tumors, and all tumors were microsatellite stable. Tumor mutational burden data were available for 72 patients; the median TMB was 3.83 mutations/Mb, and 15.3% of evaluable tumors had a TMB ≥ 10 mutations/Mb. Excluding KRAS, clinically actionable alterations were identified in 4.1% of patients, whereas an additional 32.7% harbored potentially actionable or investigational alterations. Median OS was 14.0 months (95% CI, 11.7–16.3), and median PFS was 6.0 months (95% CI, 4.3–7.7). In unadjusted analyses, OS and PFS did not differ significantly according to KRAS mutation status (OS, p = 0.967; PFS, p = 0.652), TP53 mutation status (OS, p = 0.404; PFS, p = 0.510), or KRAS variant subgroup (OS, p = 0.332; PFS, p = 0.194). In multivariable Cox analyses, KRAS mutation status was not independently associated with OS (aHR 1.13, 95% CI 0.56–2.28; p = 0.727) or PFS (aHR 1.09, 95% CI 0.59–2.01; p = 0.780), whereas ECOG performance status remained the strongest adverse clinical factor. Conclusions: In this multicenter real-world PDAC cohort, the molecular landscape was dominated by KRAS and TP53 alterations, whereas clinically actionable non-KRAS alterations were identified in only a minority of patients. After adjustment for major clinical covariates, KRAS mutation status was not independently associated with OS or PFS. Molecular profiling may still be useful for identifying uncommon potentially targetable alterations; however, larger clinically annotated multicenter studies are needed to better define its prognostic and treatment-directing value in routine practice.

9 April 2026 in Medicina
Verified
Journal Article
Open access
PDF file
AAAli Aytac
Ali Aytac
BDBilgin Demir
Bilgin Demir
MGMeltem Demirtas Gulmez
Meltem Demirtas Gulmez
HAHayati Arvas
Hayati Arvas
TTTuba Uğur Tuzcu
Tuba Uğur Tuzcu
ADAhmet Demirkazık
Ahmet Demirkazık
Background and Objectives: Serum carcinoembryonic antigen (CEA) is a widely used biomarker in non-small cell lung cancer (NSCLC). However, its association with oncogenic driver alterations and prognostic significance across molecular subtypes in metastatic disease remains insufficiently defined. Materials and Methods: This retrospective multicenter study included 332 patients with metastatic NSCLC harboring oncogenic alterations (EGFR, ALK, ROS1, KRAS, and others) from eight oncology centers in Türkiye. Baseline serum CEA levels measured at metastatic diagnosis were analyzed on the natural logarithmic scale. Associations between CEA levels, molecular subtypes, clinical features, and overall survival (OS) were evaluated using generalized linear models and Cox proportional hazards regression. Results: Baseline CEA levels differed significantly across molecular subtypes (p = 0.001), with EGFR-mutant tumors showing the highest median levels. Multivariable analysis identified driver alteration, histology, and metastatic burden as independent determinants of baseline CEA. Higher baseline CEA and metastatic site count were independently associated with increased mortality risk (HR 1.151 and 1.279 per unit increase, respectively; p < 0.001), while female sex was protective (HR 0.626; p = 0.004). KRAS mutations were associated with poorer survival compared with EGFR (HR 2.370; p < 0.001). Kaplan–Meier analyses showed a consistent trend toward longer OS in patients with CEA < 5 ng/mL, with significance only in the rare alteration subgroup. Conclusions: Baseline CEA may reflect underlying tumor biology across molecular subtypes and are associated with survival outcomes in metastatic NSCLC. However, given the variability across subgroups and modest effect sizes, these findings should be interpreted with caution. Prospective studies evaluating longitudinal CEA dynamics are warranted.

17 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NONeslihan Ozyurt
Neslihan Ozyurt
AAAli Alkan
Ali Alkan
BGBurcu Gülbağcı
Burcu Gülbağcı
MSMustafa Seyyar
Mustafa Seyyar
EAESRA AŞIK
ESRA AŞIK
MDMutlu Doğan
Mutlu Doğan
Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by substantial biological heterogeneity and variable clinical outcomes. Reliable prognostic tools are needed to improve risk stratification following neoadjuvant chemotherapy (NACT). This study aimed to evaluate the association of the Clinical–Pathologic Stage, Estrogen/Grade (CPS-EG) score with pathological complete response (pCR) and survival outcomes in patients with locally advanced TNBC treated with NACT. Methods: In this multicenter retrospective cohort study, 690 patients with locally advanced TNBC treated with NACT between 2010 and 2024 at 25 oncology centers were included. Patients were categorized according to CPS-EG score (≤3 vs. >3). Associations between CPS-EG score, clinicopathological characteristics, pCR, disease-free survival (DFS), and overall survival (OS) were analyzed. Survival outcomes were evaluated using Kaplan–Meier and Cox regression analyses. Results: Patients with a CPS-EG score > 3 had significantly lower pCR rates and higher recurrence rates compared with those with a CPS-EG score ≤ 3 (p < 0.001 for both). Five-year OS rates were 83.7% and 54.1% in the CPS-EG ≤ 3 and > 3 groups, respectively, while the corresponding five-year DFS rates were 76.4% and 51.9% (p < 0.001 for both). In the multivariable analysis, CPS-EG > 3 remained independently associated with worse OS (HR 1.46, 95% CI 1.08–1.98, p = 0.015) and DFS (HR 1.73, 95% CI 1.26–2.38, p < 0.001). Conclusions: A higher CPS-EG score is associated with a lower likelihood of achieving pCR and poorer long-term survival outcomes in patients with locally advanced TNBC treated with NACT. The CPS-EG score represents a simple and readily available tool that may support risk stratification and clinical decision-making in routine practice.